Naslov
Dietary Supplement Use and Patient Outcomes in High- Risk Early-Stage Breast Cancer

Autori
Javor, Eugen ; Lucijanić, Marko ; Skelin, Marko

Izvornik
Journal of clinical oncology (0732-183X) 38 (2020), 18; 2110-2110

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, znanstveni

Ključne riječi
Dietary Supplement Use, Patient Outcomes, High-Risk Early-Stage Breast Cancer

Sažetak
The DELCaP trial1 reported that vitamin B12 use before and during chemotherapy was significantly associated with poorer disease-free survival (DFS ; adjusted hazard ratio [adjHR], 1.83 ; 95% CI, 1.15 to 2.92 ; P < .01) and overall survival (OS) (adjHR, 2.04 [95% CI, 1.22 to 3.40] ; P < .01). A similar association for DFS was reported for use of iron supplementation during chemotherapy (adjHR, 1.79 [95% CI, 1.20 to 2.67] ; P < .01), and for DFS and OS before treatment (DFS adjHR, 1.91 [95% CI, 0.98 to 3.70] ; OS adjHR, 1.90 [95% CI, 0.90 to 4.02] ; P = .06). t would be helpful if the authors could stratify survival analyses regarding vitamin B12 and iron use by randomized treatment arms, as well as by presence of baseline anemia, and test for the interaction among supplement use, baseline anemia or hemoglobin level, and outcomes. These would help in the interpretation of observed effects and elucidation of underlying biologic mechanisms.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA